A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy

NCT02119715 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Neutropenia
Febrile Neutropenia

Interventions

DRUG: Pegylated rhG-CSF 100μg/kg
DRUG: Pegylated rhG-CSF:150 μg/kg
DRUG: rhG-CSF 5 μg/kg/day

Sponsor

Jiangsu HengRui Medicine Co., Ltd.